3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
4
Terminated
2
Completed
2
Recruiting
1
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Lymphoid
1
Conditions
Lymphoma, Large-Cell, Anaplastic
1
Granuloma, Plasma Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Suspensions
2
Powders
2
trametinib
1
talquetamab
1
taletrectinib
1
sotorasib
1
ruxolitinib
1
revumenib
1
patritumab deruxtecan
1
omburtamab I-131
1
leronlimab
1
gallium maltolate
1
dabrafenib
1
ceritinib
1
capmatinib
1
asparaginase erwinia chrysanthemi recombinant
1
apalutamide
1
Standard of Care
1
Paclitaxel
1
Nivolumab
1
HMPL-013
1
Docetaxel
1
Asparaginase
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
No longer available
×
ceritinib
×
1 year
×
Clear all
NCT05100134
2026-04-01
Managed Access Programs for LDK378, Ceritinib
Novartis
No longer available